DENVER, Colorado — September 9, 2020 — OncBioMune d/b/a Theralink Technologies (OTC: OBMP) (“Theralink” or the “Company”), a molecular profiling company specializing in patented, biomarker assay services that target multiple areas of oncology, announced today that Mick Ruxin, M.D., President and CEO of Theralink, will present at the H.C. Wainwright 22nd Annual Global Investment Conference to be held virtually on Wednesday, September 16, 2020.
Dr. Ruxin will present via live webcast at 12:30 p.m. ET. To attend, please register here: https://rb.gy/oifxe9
For more information about the H.C. Wainwright Conference, or to schedule a one-on-one meeting with Theralink’s management, please contact Theralink’s Investor Relations at Theralink@kcsa.com or H.C. Wainwright at firstname.lastname@example.org.
About Theralink® Technologies, Inc.
Theralink Technologies is a proteomics-based, molecular profiling company, located in Golden, Colorado that uniquely specializes in patented, phosphoprotein and protein biomarker assay services that target multiple areas of oncology. Theralink provides precision oncology data through its powerful Theralink® Reverse Phase Protein Array (RPPA) assays to assist the biopharmaceutical industry and clinical oncologists in identifying likely responders and non-responders to both FDA-approved and investigational drug treatments. We intend to improve cancer outcomes for patients, reveal therapeutic options for oncologists, and support biopharmaceutical drug development by using a beyond-genomics approach to molecular profiling that directly measures drug target levels and activity. For more information, please visit www.theralink.com.
Theralink Technologies, Inc.
KCSA Strategic Communications
Valter Pinto, Managing Director